Caliway Announces CBL-514 Second Phase 2b Study Results (CBL-0205) Met Endpoints
CBL-514, the world's first investigational drug for large-area localized fat reduction, has demonstrated significant efficacy in its second and the last Phase 2b study (CBL-0205) before Phase 3. 54.2% of participants in the CBL-514 group achieved at...